Apogee Pharmaceuticals, Inc. (Apogee) is focused on areas of high clinical need and is developing and acquiring targeted therapies for autoimmune and inflammatory diseases, respiratory disorders, and endometriosis while continuing to progress its existing drug candidates in the endocannabinoid system (ECS). Headquartered in Greater Vancouver, British Columbia, Canada, Apogee operates from a sophisticated 5,000-square-foot facility and wet laboratory, with a world-class team of scientists. Apogee’s mission is to translate cutting-edge science into life-changing treatments.

Apogee has a bold vision to redefine the landscape of immune-based therapeutics by combining scientific rigor with entrepreneurial agility. As an emerging biotechnology company, Apogee is dedicated to addressing diseases rooted in immune dysregulation through the pursuit of scientific innovation. Guided by a leadership team with deep expertise across the pharmaceutical, biotechnology, healthcare, financial, and legal sectors, and supported by a well-capitalized parent organization, Apogee integrates AI- and machine learning–enabled drug discovery. Apogee’s strategic focus, coupled with an unwavering commitment to improving patient outcomes, empowers Apogee to advance transformative therapies with speed and precision. Apogee’s ambitions are underpinned by strong financial support and strategic guidance enabling Apogee to move decisively, scale rapidly and pursue innovative R&D initiatives to serve unmet medical needs.